Use Circulating microRNAs as Biomarkers of Drug-Induced Liver Injury
National Center for Toxicological Research, Jefferson, Arkansas, USA
- *Corresponding Author:
- Xi Yang
US FDA NCTR, 3900 NCTR Road, Jefferson, Arkansas 72079, USA
Tel: (870) 543-7321
E-mail: [email protected]
Received Date: June 29, 2012; Accepted Date: June 29, 2012; Published Date: July 03, 2012
Citation: Yang X (2012) Use Circulating microRNAs as Biomarkers of Drug- Induced Liver Injury. J Vaccines Vaccin 3:e105. doi: 10.4172/2157-7560.1000e105
Copyright: © 2012 Yang X. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Drug-Induced Liver Injury (DILI) is an adverse event that frequently leads to cessation of drug testing in clinical trials, restrictions on drug use, and drug withdrawals. Among the preclinical candidate compounds that are discontinued for organ toxicity, it is estimated that up to half are terminated due to hepatotoxicity. Existing biomarkers of liver injury (e.g., serum alanine aminotransferase [ALT] and bilirubin) provide reasonable indicators of damage; however, none of them has sufficient specificity and/or they are increased only after significant damage has occurred. New reliable biomarkers of DILI are urgently required for both clinical and preclinical pharmaceutical evaluation. Open access helps authors, who discover new DILI biomarkers, to maximize the impact of their research articles.